These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2392321)

  • 1. [Silymarin treatment of alcoholic liver disease].
    Orv Hetil; 1990 Jul; 131(29):1607-9. PubMed ID: 2392321
    [No Abstract]   [Full Text] [Related]  

  • 2. [Alcoholic hepatopathy. Aspects of drug therapy].
    Del Dotto M; Neri D
    G Clin Med; 1982 Apr; 63(4):228-36. PubMed ID: 7128979
    [No Abstract]   [Full Text] [Related]  

  • 3. [Immunomodulator effect of silymarin therapy in chronic alcoholic liver diseases].
    Deák G; Müzes G; Láng I; Niederland V; Nékám K; Gonzalez-Cabello R; Gergely P; Fehér J
    Orv Hetil; 1990 Jun; 131(24):1291-2, 1295-6. PubMed ID: 2195425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Liver-protective action of silymarin therapy in chronic alcoholic liver diseases].
    Fehér J; Deák G; Müzes G; Láng I; Niederland V; Nékám K; Kárteszi M
    Orv Hetil; 1989 Dec; 130(51):2723-7. PubMed ID: 2574842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Use of silymarin in the treatment of alcoholic hepatic steatosis].
    Canini F; Bartolucci L; Cristallini E; Gradoli C; Rossi A; Ribacchi R; Valori C
    Clin Ter; 1985 Aug; 114(4):307-14. PubMed ID: 4053546
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment of alcoholic hepatitis with silymarin. A double-blind comparative study in 116 patients].
    Trinchet JC; Coste T; Lévy VG; Vivet F; Duchatelle V; Legendre C; Gotheil C; Beaugrand M
    Gastroenterol Clin Biol; 1989; 13(2):120-4. PubMed ID: 2707520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Oxidative stress and antioxidant defense in alcoholic liver disease and chronic hepatitis C].
    Pár A; Róth E; Rumi G; Kovács Z; Nemes J; Mózsik G
    Orv Hetil; 2000 Jul; 141(30):1655-9. PubMed ID: 10962902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Controlled study of the effect of silymarin on alcoholic liver disease].
    Bunout D; Hirsch S; Petermann M; de la Maza MP; Silva G; Kelly M; Ugarte G; Iturriaga H
    Rev Med Chil; 1992 Dec; 120(12):1370-5. PubMed ID: 1343377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver cell protection in toxic liver lesion.
    Fehér J; Cornides A; Pál J; Láng I; Csomós G
    Acta Physiol Hung; 1989; 73(2-3):285-91. PubMed ID: 2596318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical experience with silymarin in the treatment of chronic liver disease(author's transl)].
    Reutter FW; Haase W
    Schweiz Rundsch Med Prax; 1975 Sep; 64(36):1145-51. PubMed ID: 1099576
    [No Abstract]   [Full Text] [Related]  

  • 11. [Evaluation of the therapeutic effects of silymarin].
    Margaroli P; Rossi M; Arcabasso GD; Cosini I; Malacrida C
    Clin Ter; 1980 Dec; 95(6):663-72. PubMed ID: 7214856
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effect of silimarin (Legalon) therapy on the antioxidant defense mechanism and lipid peroxidation in alcoholic liver disease (double blind protocol)].
    Müzes G; Deák G; Láng I; Nékám K; Niederland V; Fehér J
    Orv Hetil; 1990 Apr; 131(16):863-6. PubMed ID: 2345633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of alcoholic liver disease].
    Fehér J; Krisztina H
    Orv Hetil; 2003 Jun; 144(26):1305-6. PubMed ID: 12894675
    [No Abstract]   [Full Text] [Related]  

  • 14. [Uses of silymarin in the treatment of symptomatic hepatic porphyria (author's transl)].
    Kordac V; Kaláb M
    Cas Lek Cesk; 1977 Apr; 116(13):407-10. PubMed ID: 861998
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effect of the administration of silymarin on serum lipid levels].
    Petronelli A; Roda E; Briganti M; Morselli Labate AM; Barbara L
    Clin Ter; 1981 Dec; 99(5):471-82. PubMed ID: 7333068
    [No Abstract]   [Full Text] [Related]  

  • 16. [A two-center study on the effects of silymarin in pregnant women and adult patients with so-called minor hepatic insufficiency].
    Giannola C; Buogo F; Forestiere G; Scaffidi L; Ferrigno V; Scaffidi A
    Clin Ter; 1985 Jul; 114(2):129-35. PubMed ID: 4053531
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of alcoholic liver diseases. Abstinence, nutritional support, drug therapy, liver transplantation].
    Pár A
    Orv Hetil; 2000 Apr; 141(16):827-33. PubMed ID: 10817009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The influence of therapy with silymarin on the survival rate of patients with liver cirrhosis (author's transl)].
    Benda L; Dittrich H; Ferenzi P; Frank H; Wewalka F
    Wien Klin Wochenschr; 1980 Oct; 92(19):678-83. PubMed ID: 7008367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Milk thistle (Silybum marianum) derivatives in the therapy of chronic hepatopathies].
    De Martiis M; Fontana M; Assogna G; D'Ottavi R; D'Ottavi O
    Clin Ter; 1980 Aug; 94(3):283-315. PubMed ID: 7004762
    [No Abstract]   [Full Text] [Related]  

  • 20. [Sylimarine in the treatment of chronic hepatitis].
    Sawaryn T; Szymoński K; Machalska M
    Przegl Epidemiol; 1977; 31(4):445-50. PubMed ID: 607279
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.